

PATENT  
ST98009AIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): BYK ET AL. EXAMINER : W. ALVARADO  
 SERIAL NO. : 09/647,678 ART UNIT :  
 FILED : OCTOBER 2, 2000  
 FOR : NEW AGENTS FOR TRANSFERRING NUCLEIC ACIDS,  
 COMPOSITIONS CONTAINING THEM AND THEIR USES

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231 on July 3, 2001.

William C. Coppola, Reg. No. 41,686  
 (Name of Registered Representative)

Penelia Walker  
 (Signature and Date)

INFORMATION DISCLOSURE STATEMENT UNDER  
 37 C.F.R. 1.56, 1.97 AND 1.98

ASSISTANT COMMISSIONER FOR PATENTS  
 WASHINGTON, D.C. 20231

Dear Sir:


Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication, or other information referred

to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

This Information Disclosure Statement is filed within the period set forth in §1.97(b)(3), because it is being filed before the mailing of a first office action on the merits. However, if it is subsequently determined that this information disclosure statement has been filed after the mailing of a first office action, the Commissioner is hereby authorized to charge any fee due under 37 C.F.R. 1.17(P), or credit any overpayment, to account No. 18-1982.

Applicants concurrently submit herewith a PTO-1449 form and copies of references listed therein.

Respectfully submitted,



---

William C. Coppola  
Attorney for Applicants  
Registration No. 41,686

Aventis Pharmaceuticals Products Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-4854

